跳至主要内容
临床试验/JPRN-jRCT1080222429
JPRN-jRCT1080222429已完成未知

36-month Special Drug Use Surveillance on Frequency of Bone Fractures with Benet 75 mg Tablets

Takeda Pharmaceutical Company Limited0 个研究点目标入组 579 人开始时间: 2014年3月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
579

研究概览

简要总结

In conclusion, no new problem of Benet was detected in terms of the safety or efficacy in clinical settings. In addition, as high as 83.24% to 95.38% of patients took the drug as instructed by a physician from the start of Benet treatment to the 36th dose (3 years), and the median dosing interval between two consecutive doses was 30.0 to 31.0 days, showing a good treatment status. Refer to summary of the special drug use surveillance in "Secondary Outcome Measures" section for others.

研究设计

研究类型
Observational

入排标准

年龄范围
>= 50age old 至 ot applicable(—)
性别
All

入选标准

  • Osteoporosis patients who meet all the following criteria:
  • 1. Patients with 1 to 4 confirmed vertebral body fractures in the T4-L4 region by thoracic and lumbar spine X-ray examination at screening (within 3 months before the start of administration of sodium risedronate 75 mg tablets)
  • 2. Male and postmenopausal female patients aged 50 years or older
  • 3. Ambulatory outpatients

排除标准

  • 未提供

研究者

相似试验